Investors never know what to expect for Enzo Biochem
What analysts say:
- Buy, sell, or hold?: Analysts are very bullish on this stock, unanimously backing it as a buy. Enzo Biochem's rating hasn't changed over the past three months.
- Revenue Forecasts: On average, analysts predict $27.6 million in revenue this quarter. That would represent a rise of 10.8% from the year-ago quarter.
- Wall Street Earnings Expectations: The average analyst estimate is a loss of $0.09 per share.
What our community says:
CAPS All-Stars are solidly backing the stock with 86.7% giving it an "outperform" rating. The community at large backs the All-Stars with 85.5% awarding it a rating of "outperform." Fools are gung-ho about Enzo Biochem, though the message boards have been quiet lately, with only 35 posts in the past 30 days. Enzo Biochem's bearish CAPS rating of two out of five stars falls short of the Fool community sentiment.
Revenue has now gone up for three straight quarters. The company boosted its gross margin by 2.4 percentage points in the last quarter. Revenue rose 8.6% while cost of sales rose 3.7% to $13.5 million from a year earlier.
Now let's look at how efficient management is at running the business. Traditionally, margins represent the efficiency with which companies capture portions of sales dollars. The following table shows gross, operating, and net margins over the past four quarters.
For all our Enzo Biochem-specific analysis, including earnings and beyond, add Enzo Biochem to My Watchlist.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.